Skip to main content
AAO-HNSF 2025 Annual Meeting & OTO EXPO Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Rate ePoster
Video

Head and Neck Surgery

(A587) Nutritional and Immunological Status in Head and Neck Cancer Prognosis

Monday, October 13, 2025
12:00 PM - 1:00 PM EDT
Location: OTO EXPO, Posters

    Presenting Author(s)

  • Ching-Yi Yiu, MD

    Chief
    Department of Otolaryngology , Yumin Medical Corporation Yumin Hospital, Caotun, Nantou, Taiwan
    TAINAN, Tainan, Taiwan (Republic of China)

    • Co-Author(s)

  • Hui-Chen Hsu, MD

    Attending Physician
    Department of Otolaryngology , Kuang Tien General Hospital, Taichung, Taiwan
    TAINAN TAIWAN, Tainan, Taiwan (Republic of China)

  • YY

    Yun-Hsin Yu, MD

    Postgraduate Year
    Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China)
    Tainan, Tainan, Taiwan (Republic of China)

    • Senior Author(s)

  • CH

    Chia-Yun Hsieh, MD

    Director
    Department of Neurology , Yumin Medical Corporation Yumin Hospital, Nantou, Taiwan
    Caotun, Nantou, Taiwan (Republic of China)

Disclosure(s):
Ching-Yi Yiu, MD: No relevant relationships to disclose.
Hui-Chen Hsu, MD: No relevant relationships to disclose.


Introduction: The pretreatment nutritional and immunological status of HNC patients are reliable prognostic indicators of tumor outcomes and survival. This study retrospectively reviews these factors in our HNC patients.

Methods: A retrospective review was conducted on 60 head and neck cancer (HNC) patients in 2024.The cases include 21 hypopharyngeal cancers (35%), 9 laryngeal cancers (15%), 6 each of tongue and tonsillar cancers (10% each), 5 each of tongue base and soft palate cancers (8.33% each), 2 each of buccal mucosa, mouth floor, and retromolar trigone cancers (3.33% each), and 1 each of low lip and hard palate cancers (1.67% each). All patients received surgical resection and/or adjuvant radiotherapy or concurrent chemoradiotherapy based on pathological results. We measured body weight (BW), body mass index (BMI), albumin, and hemoglobin (Hb) at pretreatment, and at 3 and 6 months post-treatment. We also evaluated C-reactive protein (CRP), platelet count, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) to assess immunological status. We analyzed how these indicators impact the prognosis of head and neck cancer (HNC) patients.

Results: Among the patients, 6 (10%) experienced wound infection, 2 (3.33%) developed pharyngocutaneous fistula, 2 (3.33%) had flap necrosis, and 6 (10%) resulted in mortality. In the wound infection group, the average BMI is 20.4, the average Hb is 12.9 g/dL, the average albumin is 3.5 g/dL, the average NLR is 6.78, and the PLR is 243.5. In the PC fistula and flap necrosis group, the average BMI is 21.65, the average Hb level is 11.7 g/dL, the average albumin level is 3.15 g/dL, the average NLR is 13.28, and the PLR is 418.84. In the mortality group, the average BMI is 22.3, the average Hb level is 13.58 g/dL, the average albumin level is 3.77 g/dL, the average NLR is 6.06, and the PLR is 275.5.

Conclusions: HNC is a significant global health issue. Our study found that the average BMI was below 22, Hb. under 12.0 g/dL, albumin below 3.3 g/dL, NLR below 3, and PLR above 170. HNC patients will have a high rate of surgical complications and mortality.